Vigilance
Pharmacovigilance
The Department of Pharmacovigilance was set up in late 2004 at the Pharmacy and Poisons Board with a vision to develop, implement and continuously upgrade an appropriate system for detecting, reporting and monitoring adverse drug reactions (ADRs) and other relevant problems with medicines in Kenya. The department strives to ensure the safety and efficacy of pharmaceutical products in Kenya.
Pharmacovigilance is the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other possible drug-related problems with the view to:
Early detection of hitherto unknown adverse reactions and interactions
Detection of increases in frequency of (known) adverse reactions
Identification of risk factors and possible mechanisms underlying adverse reactions
Estimation of quantitative aspects of benefit/risk analysis and dissemination of information needed to improve drug prescribing and regulation.
Goals of Pharmacovigilance
- The rational and safe use of medicines.
- The assessment and communication of the risks and benefits of drugs on the market.
- Educating and informing patients.
Guidelines and the tools to implement Pharmacovigilance in Kenya have been developed and sensitization workshops have been carried out for various cadres of health professionals in Kenya such as Pharmacists, Pharmaceutical technologists, nurses, Clinicians and Clinical officers. The system plans to cover all provinces, for all medicines and for all patients. All manufacturers and distributors are expected to submit all findings and reports on adverse events with drugs to PPB.
Scientific Publications
Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania
Barry A, Olsson S, Minzi O, Bienvenu E, Makonnen E, Kamuhabwa A, Oluka M, Guantai A, Bergman U, van Puijenbroek E, Gurumurthy P, Aklillu E. Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania.
Drug Saf. 2020Apr;43(4):339-350. doi: 10.1007/s40264-019-00898-z. PMID: 31919794; PMCID: PMC7105440.
The challenging times and opportunities for pharmacovigilance in Africa during the COVID-19 pandemic
Ogar, C., Mathenge, W., Khaemba, C., & Ndagije, H. (2020). The challenging times and opportunities for pharmacovigilance in Africa during the COVID-19 pandemic. Drugs & therapy perspectives: for rational drug selection and use, 36(8), 351–354.
Comparative Assessment of the Pharmacovigilance Systems within the Neglected Tropical Diseases Programs in East Africa—Ethiopia, Kenya, Rwanda, and Tanzania
Barry A, Olsson S, Khaemba C, Kabatende J, Dires T, Fimbo A, Minzi O, Bienvenu E, Makonnen E, Kamuhabwa A, Oluka M, Guantai A, van Puijenbroek E, Bergman U, Nkayamba A, Mugisha M, Gurumurthy P, Aklillu E. Comparative Assessment of the Pharmacovigilance Systems within the Neglected Tropical Diseases Programs in East Africa—Ethiopia, Kenya, Rwanda, and Tanzania. International Journal of Environmental Research and Public Health. 2021; 18(4):1941.
Safety and Tolerability of Mass Diethylcarbamazine and Albendazole Administration for the Elimination of Lymphatic Filariasis in Kenya: An Active Surveillance Study
Khaemba, C.; Barry, A.; Omondi, W.P.; Bota, K.; Matendechero, S.; Wandera, C.; Siyoi, F.; Kirui, E.; Oluka, M.; Nambwa, P.; Gurumurthy, P.; Njenga, S.M.; Guantai, A.; Aklillu, E. Safety and Tolerability of Mass Diethylcarbamazine and Albendazole Administration for the Elimination of Lymphatic Filariasis in Kenya: An Active Surveillance Study. Pharmaceuticals 2021, 14, 264.
2024/2025 FY
2023/2024 FY
2022/2023 FY
- Pharmacovigilance October – December 2022 Q2 Report
- Pharmacovigilance July – September 2022 Q1 Report
2021/2022 FY
2020/2021 FY
2019/2020 FY
2018/2019 FY